The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: Findings from the Euro Heart Survey of stable angina

European Heart Journal

Volumn 27, Issue 11, 2006, Pages 1298-1304

  Daly, Caroline ^a   Clemens, Felicity ^b   Lopez Sendon, Jose L ^c   Tavazzi, Luigi ^d   Boersma, Eric ^e   Danchin, Nicholas ^f   Delahaye, Francois ^g   Gitt, Anselm ^h   Julian, Desmond ⁱ   Mulcahy, David ^j   Ruzyllo, Witold ^k   Thygesen, Kristian ^l   Verheugt, Freek ^m   Fox, Kim M ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g LOUIS PRADEL HOSPITAL   (France)

^h Herzzentrum Luwigshafen   (Germany)

ⁱ NEWCASTLE UNIVERSITY   (United Kingdom)

^j ADELAIDE AND MEATH HOSPITAL   (Ireland)

^k INSTITUTE OF CARDIOLOGY   (Poland)

^l AARHUS UNIVERSITY HOSPITAL   (Denmark)

^m RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Evidence based therapy; Guideline compliance; Prognosis; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICORANDIL; NITRATE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; DIAGNOSTIC VALUE; EUROPE; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; STABLE ANGINA PECTORIS; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANGINA PECTORIS; EUROPE; EVIDENCE-BASED MEDICINE; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 33745683661     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehl005     Document Type: Article

References (29)

1. Boersma E, Manini M, Wood DA et al. Cardiovascular Diseases in Europe. Euro Heart Survey and National Registries of Cardiovascular Diseases and Patient Management. Sophia Antipolis, France, ESC; 2002.
2. Phillips SJ, Whisnant JP, O Fallon WM, Frye RL. Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minnesota. Mayo Clin Proc 1990;65:344-359.
3. Mittlemark MB, Psaty BM, Rautaharju PM, Fried LP, Borhani NO, Tracy RP, Gardin JM, O'Leary DH. for the Cardiovascular Health Study Collaborative Research Group. Prevalence of cardiovascular diseases in older adults. Am J Epidemiol 1993;137:311-317.
4. Smith W, Kenicer M, Tunstall-Pedoe H, Clark E, Crombie I. Prevalence of coronary heart disease in Scotland: Scottish Heart Study. Br Heart J 1990;65:344-359.
5. Shaper A, Cook D, Walker M, Mc Farlane P. Prevalence of ischaemic heart disease in middle aged British men. Br Heart J 1984;51:595-605.
6. Sigurdsson E, Thorgeirsson G, Sigvaldason H, Sigfusson N. Prevalence of coronary heart disease in Icelandic Men 1968-1986. The Reykjavik Study. Eur Heart J 1993;14:584-591.
7. Recommendations of the Task Force of the European Society of Cardiology. Management of stable angina pectoris. Eur Heart J 1997;18:394-413.
8. The Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J 1988;9:8-16.
9. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta-Blockade during and after myocardial infarction: an overview of the randomised trials. Prog Cardiovasc Dis 1985;27:335-371.
10. Daly C, Clemens F, Sendon JL, Tavazzi L, Boersma E, Danchin N, Delahaye F, Gitt A, Julian D, Mulcahy D, Ruzyllo W, Thygesen K, Verheugt F, Fox KM, Euro Heart Survey Investigators. The clinical characteristics and investigations planned in patients with Stable Angina presenting to cardiologists in Europe, from the Euro Heart Survey of Stable Angina. Eur Heart J 2005;26:996-1010.
11. Daly C, Clemens F, Sendon JL, Tavazzi L, Boersma E, Danchin N, Delahaye F, Gitt A, Julian D, Mulcahy D, Ruzyllo W, Thygesen K, Verheugt F, Fox KM, Euro Heart Survey Investigators. The Initial Management of Stable Angina in Europe, from the Euro Heart Survey - a description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the Euro Heart Survey of Stable Angina. Eur Heart J 2005;26:1011-1020.
12. Clayton D, Hills M. Statistical Models in Epidemiology. OUP; 1993.
13. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393.
14. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr, Gardin JM, O'Rourke RA, Pasternak RC, Williams SV, Gibbons RJ, Alpert JS, Antman EM, Hiratzka LF, Fuster V, Faxon DP, Gregoratos G, Jacobs AK, Smith SC Jr, American College of Cardiology; American Heart Association Task Force on Practice Guidelines. Committee on the Management of Patients With Chronic Stable Angina ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003;107:149-158.
15. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary disease: randomised, double blind, placebo-controlled, multi-centre trail (the EUROPA study). Lancet 2003;362:782-788.
16. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New Engl J Med 2000;342:145-153.
17. The PEACE Trial Investigators. Angiotensin converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-2068.
18. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta-blockade after myocardial infarction: systematic review meta regression analysis. BMJ 1999;318:1730-1737.
19. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
20. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340-2346.
21. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, Keech A, Packard C, Simes J, Byington R, Furberg CD, for the Prospective Pravastatin Pooling Project Investigators Group. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation 2000;102:1893-1900.
22. Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004;57:640-651.
23. Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-2016.
24. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-1158.
25. Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.
26. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
27. Goldberg RB, Mellies MJ, Sacks FM et al., for the CARE Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation 1998;98:2513-2519.
28. Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation 2004;109:745-749.
29. Spertus JA, Salisbury AC, Jones PG, Conaway DG, Thompson RC. Predictors of quality-of-life benefit after percutaneous coronary intervention. Circulation 2004;110:3789-3794.